Swiss National Bank Cassava Sciences Inc Transaction History

Swiss National Bank

$146 Billion
Q4 2024

A detailed history of Swiss National Bank transactions in Cassava Sciences Inc stock. As of the latest transaction made, Swiss National Bank holds 89,000 shares of SAVA stock, worth $226,949. This represents 0.0% of its overall portfolio holdings.

Number of Shares

89,000

Previous 89,000 -0.0%

Holding current value

$226,949

Previous $2.62 Million 91.98%

% of portfolio

0.0%

Previous 0.0%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 07, 2024	BUY	$9.57 - $35.08 $79,431 - $291,164	8,300 Added 10.29%	89,000 $2.62 Million
Q2 2024 Aug 08, 2024	BUY	$12.35 - $26.11 $25,935 - $54,831	2,100 Added 2.67%	80,700 $996,000
Q4 2023 Feb 06, 2024	SELL	$12.64 - $30.11 $108,704 - $258,946	-8,600 Reduced 9.86%	78,600 $1.77 Million
Q3 2023 Nov 08, 2023	BUY	$16.64 - $25.32 $13,312 - $20,256	800 Added 0.93%	87,200 $1.45 Million
Q2 2023 Aug 09, 2023	BUY	$21.59 - $27.88 $17,272 - $22,304	800 Added 0.93%	86,400 $2.12 Million
Q1 2023 May 10, 2023	SELL	$23.46 - $36.44 $147,798 - $229,572	-6,300 Reduced 6.86%	85,600 $2.06 Million
Q4 2022 Feb 08, 2023	BUY	$27.82 - $44.16 $58,422 - $92,736	2,100 Added 2.34%	91,900 $2.71 Million
Q1 2022 May 09, 2022	BUY	$32.6 - $53.05 $189,080 - $307,690	5,800 Added 6.9%	89,800 $3.34 Million
Q3 2021 Nov 08, 2021	BUY	$41.79 - $135.3 $96,117 - $311,190	2,300 Added 2.82%	84,000 $5.22 Million
Q2 2021 Aug 06, 2021	BUY	$32.15 - $89.72 $2.63 Million - $7.33 Million	81,700 New	81,700 $6.98 Million

Others Institutions Holding SAVA

# of Institutions

190

Shares Held

16.4M

Call Options Held

3.49M

Put Options Held

8.08M

View Full List

About CASSAVA SCIENCES INC

Ticker SAVA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,097,900
Market Cap $102M
Description
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's...

More about SAVA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Swiss National Bank, based on Form 13F filings with the SEC.

News

Stay updated on Swiss National Bank with notifications on news.

Account

Swiss National Bank Cassava Sciences Inc Transaction History